Shuttle Pharmaceuticals

Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company focused on improving the efficacy of radiation therapy for cancer patients. The company develops novel radiation sensitizers designed to increase the sensitivity of cancer cells to radiation while minimizing damage to healthy tissue. Its lead candidate, ROPES (SP-1-161), is a selective histone deacetylase (HDAC) inhibitor being evaluated for the treatment of glioblastoma and other solid tumors. By leveraging its proprietary platform, Shuttle Pharmaceuticals aims to address the limitations of current radiation treatments and improve outcomes for patients with high-unmet-need cancers.